American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Radiopharm Theranostics Ltd

$4.31 +1.41% NASDAQ: RADX · 15-min delayed

Public · NASDAQ: RADX
14 employees

Visit website Follow

$34.1MMarket cap

14Employees

RADXNASDAQ

2024IPO

About Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: RADX
Employees: 14
IPO date: Nov 27, 2024
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: RADX Nasdaq
SEC CIK: 1949257
SIC: 2834 Pharmaceutical Preparations

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Radiopharm Theranostics Ltd and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Market cap: $34.1M

NASDAQ: RADX

$4.31 +1.41%

15-minute delayed · data by Polygon.io

Past year

$3.84 $10.63

52-week range

Market cap: $34.1M
Shares outstanding: 7.9M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 27, 2024

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Trading 59% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Radiopharm Theranostics Ltd.

Write a review